W. Marston Linehan, MD, chief, Urologic Oncology Branch, National Cancer Institute, discusses the treatment of hereditary leiomyomatosis and renal cell cancer (HLRCC).
W. Marston Linehan, MD
Advertisement
Articles by W. Marston Linehan, MD
W. Marston Linehan, MD, chief, Urologic Oncology Branch, National Cancer Institute, discusses gene mutations in papillary kidney cancer.
W. Marston Linehan, MD, chief, Urologic Oncology Branch, National Cancer Institute, discusses genetic conditions with predisposition for patients with kidney cancer.
Advertisement
Latest Updated Articles
Dr. Linehan on Genes With Predisposition to Kidney CancerPublished: February 24th 2017 | Updated:
Dr. Linehan on Gene Mutations in Papillary Kidney CancerPublished: March 10th 2017 | Updated:
Dr. Linehan on Treatment for Hereditary Leiomyomatosis and RCCPublished: April 4th 2017 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
The OncFive: Top Oncology Articles for the Week of 1/25
3
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
4
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
5